by RecursionUS
An AI-designed MEK1/2 inhibitor for familial adenomatous polyposis (FAP), a genetic disorder causing hundreds to thousands of polyps in the colon. Targets polyp reduction without cell toxicity.
Phase 1b/2 TUPELO trial ongoing. FDA meeting planned for H2 2026 to define registration path.
Updated 5 May 2025Checked 10 Oct0 updates this week
MEK is a kinase that relays growth signals from cell surface receptors. Blocking it stops the cascade that tells polyp cells to divide.
Recursion's platform screened cell models of FAP to identify compounds that reduce polyp growth, then used AI to match the compound to its molecular target.
| Spec | REC-4881 |
|---|---|
| Target | MEK1/2 kinaseR (reported) |
| Mechanism | MEK1/2 kinase inhibitorR (reported) |
| Median polyp burden reduction at week 13 | 43%R (reported) |
| Response rate at week 13 | 75%R (reported) |
R reported by the company
Recursion
AI drug discovery from cell images
Salt Lake City company that photographs millions of cell experiments, then uses AI to spot patterns and find drug candidates. It merged with Exscientia in Nov 2024 and, after cuts in 2025, has a new CEO focused on proving results in trials.
